GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DocGo Inc (NAS:DCGO) » Definitions » Cash Flow from Financing

DocGo (DCGO) Cash Flow from Financing : $12.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is DocGo Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, DocGo paid $4.9 Mil more to buy back shares than it received from issuing new shares. It received $4.0 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It spent $0.0 Mil on other financial activities. In all, DocGo spent $0.9 Mil on financial activities for the three months ended in Mar. 2024.


DocGo Cash Flow from Financing Historical Data

The historical data trend for DocGo's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DocGo Cash Flow from Financing Chart

DocGo Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
56.34 -0.81 155.21 -6.18 1.12

DocGo Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.95 8.76 -8.67 12.98 -0.88

DocGo Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

DocGo's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

DocGo's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DocGo  (NAS:DCGO) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

DocGo's issuance of stock for the three months ended in Mar. 2024 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

DocGo's repurchase of stock for the three months ended in Mar. 2024 was $-4.9 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

DocGo's net issuance of debt for the three months ended in Mar. 2024 was $4.0 Mil. DocGo received $4.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

DocGo's net issuance of preferred for the three months ended in Mar. 2024 was $0.0 Mil. DocGo paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

DocGo's cash flow for dividends for the three months ended in Mar. 2024 was $0.0 Mil. DocGo received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

DocGo's other financing for the three months ended in Mar. 2024 was $-0.0 Mil. DocGo spent $0.0 Mil on other financial activities.


DocGo Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of DocGo's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


DocGo (DCGO) Business Description

Traded in Other Exchanges
N/A
Address
35 West 35th Street, Floor 6, New York, NY, USA, 10001
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. DocGo is disrupting the traditional four-wall healthcare system by providing care at the scale of humanity. Its technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace.
Executives
Stephen Sugrue officer: Chief Compliance Officer 35 WEST 35TH STREET, FLOOR 6, NEW YORK NY 10001
Lee Bienstock officer: Chief Operating Officer 35 WEST 35TH STREET, FLOOR 6, NEW YORK NY 10001
Ely D Tendler director, officer: General Counsel, Secretary STRATEGIC AND LEGAL SERVICES, PLLC, 54 LAWRENCE AVENUE, LAWRENCE NY 11559
Anthony Capone officer: President 106 DUANE ST., #3, NEW YORK NY 10007
Adriaan Stephanus Oberholzer officer: Chief Financial Officer 35 W 35TH STREET, 6TH FLOOR, NEW YORK NY 10001
James M Travers director C/O FLEETMATICS, 1100 WINTER STREET, 4TH FL, WALTHAM MA 02451
Etalvina Leite director 5477 VIA NICOLA, NEWBURY PARK CA 91320
Michael J Burdiek director 39 PARKER, IRVINE CA 92618
Ira Smedra director 401 N. JUNE STREET, LOS ANGELES CA 90004
Mark Do Merlin officer: CMO, Ambulnz Holdings, LLC 35 W 35TH STREET, NEW YORK NY 10001
Michael S. Witkowski officer: Chief Compliance Officer PO BOX 10482, NEWBURGH NY 12552
Christopher Fillo director 3110 MAIN STREET, SUITE 310, SANTA MONICA CA 90405
Norman Rosenberg officer: CFO, Ambulnz Holdings, LLC 51 MOUNTAIN AVENUE, MONSEY NY 10952
Stanley Vashovsky director, 10 percent owner, officer: Chief Executive Officer 763 RALEIGH STREET, WOODMERE NY 11598
Steven Katz director 20 REBEL RUN DR, EAST BRUNSWICK NJ 08816

DocGo (DCGO) Headlines

From GuruFocus